anti-Nipah_018
| anti-Nipah_ID | anti-Nipah_018 |
| anti-Nipah Drug | {2,2,2-trifluoro-N-[3-(N-naphthylcarbamoyl)(4,5,6,7-tetrahydrobenzo [beta]thiophen-2-yl)]acetamide |
| Nipah virus strain | NiV (Malaysia-1999) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | 293T |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 0.2 TCID50/cell |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Post infection (2 hour) |
| Duration of Drug delivery for anti-Nipah activity | 48 hours |
| Drug concentration used to test anti-Nipah activity | 0.029 μM |
| Assays used to test anti-Nipah activity | TCID50 |
| anti-Nipah activity | Decrease [Effective concentration (50 %)] |
| References | Lo MK, Nichol ST, Spiropoulou CF Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. |
| Comments | The use of fluorescent and luminescent reporter NiVs for antiviral screening was evaluated. The 50% effective concentrations (EC50s) derived for inhibitors against both reporter viruses were within range of EC50s derived from virus yield-based dose?response assays against wild-type NiV (within 1Log10), thus demonstrating that both reporter NiVs can serve as robust antiviral screening tools. These reporter NiVs will not only facilitate antiviral screening, but also the study of host cell components that influence the virus life cycle. |